报告期内，本集团持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫 苗曼海欣收入保持持续增长。同时，本集团深入推进降本增效，各项费用得到有效管控；产销协同进一 步优化，毛利率亦有所提升。本集团整体盈利能力显着提升，成功于报告期实现归属于母公司所有者的 净利润为正。 消息面上，康希诺生物发布年度业绩快报，营业总收入10.68亿元人民币，同比增长26.18%；归属于母 公司所有者的净利润2787.27万元，同比扭亏为盈。 智通财经APP获悉，康希诺生物(06185)绩后涨超5%，截至发稿，涨4.88%，报34.8港元，成交额1499.79 万港元。 ...

康希诺生物(06185)绩后涨超5%，截至发稿，涨4.88%，报34.8港元，成交额1499.79万港元。 报告期内，本集团持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫 苗曼海欣收入保持持续增长。同时，本集团深入推进降本增效，各项费用得到有效管控；产销协同进一 步优化，毛利率亦有所提升。本集团整体盈利能力显着提升，成功于报告期实现归属于母公司所有者的 净利润为正。 消息面上，康希诺生物发布年度业绩快报，营业总收入10.68亿元人民币，同比增长26.18%；归属于母 公司所有者的净利润2787.27万元，同比扭亏为盈。 ...

报告期内，营业利润、利润总额及归属于母公司所有者的净利润均同比实现扭亏为盈；基本每股收益、 加权平均净资产收益率由负转正；归属于母公司所有者的扣除非经常性损益的净亏损同比收窄，上述变 动主要系：报告期内，集团营业总收入同比增长26.18%，集团持续优化资源配置、推行降本增效措 施，经营效率持续提升，报告期内多项费用实现节约，亦实现与政府专项补助和国际专项研发资金支持 相关的收益，因此，报告期多项盈利能力相关的主要财务数据和指标实现同比正增长。 格隆汇2月26日丨康希诺生物(06185.HK)披露2025年度业绩快报公告，2025年度集团实现营业总收入约 为人民币1,067.91百万元，同比增长26.18%；实现归属于母公司所有者的净利润约为人民币27.87百万 元，与上年同期相比，将实现扭亏为盈；实现归属于母公司所有者的扣除非经常性损益的净亏损约为人 民币92.50百万元。 报告期内，集团持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫苗 曼海欣?入保持持续增长。同时，集团深入推进降本增效，各项费用得到有效管控；产销协同进一步优 化，毛利率亦有所提升。集团整体盈利能力显著提升，成功于 ...

经济观察网康希诺生物近期在研发与财务方面取得重要进展。PCV24疫苗获批临床试验，2025年业绩预 计扭亏为盈，多项产品商业化持续推进。 公司项目推进 2026年1月6日，康希诺生物宣布其自主研发的24价肺炎球菌多糖结合疫苗(PCV24)获得国家药品监督管 理局批准开展临床试验。该产品是全球首个进入临床阶段的24价肺炎结合疫苗，采用双载体技术，覆盖 24种血清型，有望填补市场空白。临床试验的启动是公司技术平台升级的关键里程碑。 最近业绩情况 2026年1月27日，公司发布业绩预告，预计2025年年度实现营业收入10.40亿至10.80亿元，同比增长 22.88%至27.61%；归属于母公司所有者的净利润为2450万至2900万元，同比扭亏为盈。扭亏主要得益 于四价流脑结合疫苗曼海欣的持续放量、成本管控优化及非经常性收益。 业务与技术发展 百白破组分疫苗已完成三期临床，预计2026年上半年获批。曼海欣在印度尼西亚获得清真认证并实现出 口，公司正深化海外临床合作，聚焦东南亚、中东等新兴市场。13价肺炎结合疫苗优佩欣于2025年9月 上市，正加速市场准入；多项在研疫苗处于临床阶段。 以上内容基于公开资料整理，不构成 ...

百余家医药企业发布业绩预告 19家年内实现业绩翻身 1月30日，新京报贝壳财经记者根据Wind数据整理发现，474家医药企业中，255家已发布2025年业绩预告。81家企业释放出积极信号，其中，50家企业出现 业绩预增，6家业绩略增。 | 业绩预告类型 | 数量 | | --- | --- | | 不确定 | 1 | | 略減 | 3 | | 略增 | 6 | | 扭亏 | 24 | | 首亏 | 38 | | 续亏 | 90 | | 续盈 | 1 | | 预减 | 42 | | 预增 | 50 | | 总数 | 255 | 近日，A股医药板块上市公司开始密集披露2025年度业绩预告。据新京报贝壳财经统计，截至1月30日，已有255家相关企业公布了业绩预告数据。 其中超三成企业释放积极信号——50家业绩预增、24家实现扭亏，打赢"翻身仗"，化学制药、医疗器械、医疗服务等领域企业表现突出。 值得注意的是，海外市场成为多家企业增长的共同引擎。以理邦仪器为例，公司在业绩预告中强调"国际市场保持两位数增长"。与此同时，部分企业通过降 本增效、产品结构调整成功实现业绩逆转。 行业内部亦呈现结构性分化，从2025年业绩表 ...

报告期内，公司持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫苗 曼海欣 收入保持持续增长。同时，公司深入推进降本增效，各项费用得到有效管控；产销协同进一步 优化，毛利率亦有所提升。整体盈利能力显著提升，成功于报告期实现归属于母公司所有者的 近日，康希诺发布公告称，经公司财务部门初步测算，预计2025年年度实现营业收入10.4亿元到10.8亿 元，同比增长22.88%到27.61%。预计2025年年度实现归属于母公司所有者的净利润为2450万元到2900 万元，与上年同期相比，将实现扭亏为盈。 ...

Core Viewpoint - The company, CanSino Biologics (06185), anticipates significant revenue growth and a turnaround in profitability by the end of 2025, driven by innovative product offerings and effective cost management [1] Financial Projections - The company expects to achieve operating revenue between RMB 1.04 billion and RMB 1.08 billion for the year ending December 31, 2025, representing an increase of RMB 194 million to RMB 234 million compared to the previous year, which translates to a year-on-year growth of 22.88% to 27.61% [1] - The projected net profit attributable to the owners of the parent company is expected to be between RMB 24.5 million and RMB 29 million, indicating a return to profitability compared to the previous year [1] - The expected net loss attributable to the owners of the parent company, after excluding non-recurring gains and losses, is projected to be between RMB 91 million and RMB 96 million [1] Strategic Focus - The company continues to implement a development strategy centered on innovation and commercialization, with the first four-valent meningococcal vaccine, Manhaixin, showing sustained revenue growth [1] - The company has made significant progress in cost reduction and efficiency improvement, effectively managing various expenses, which has led to an increase in gross margin [1] - Overall profitability has significantly improved, achieving a positive net profit attributable to the owners of the parent company during the reporting period [1] Research and Funding - The rapid advancement of the company's R&D projects and international collaborations has resulted in increased government grants and international funding support, contributing to substantial non-recurring income during the reporting period [1]

Core Viewpoint - The A-share and Hong Kong stock pharmaceutical sectors have shown significant structural differentiation in 2023, with the innovative drug sector recovering in valuation due to policy relaxation and global collaboration, while the vaccine sub-sector lags behind due to price wars and a shrinking infant vaccination population [1][2]. Industry Analysis - The vaccine industry is at a critical juncture of "pain and opportunity," facing traditional price competition that squeezes profit margins, while high-end products and new market segments (like adult and overseas markets) are emerging as potential growth paths for companies with technological barriers [1][3]. - The vaccine sector is undergoing a "pressure test" in 2024, with a significant decline in revenue and profit due to homogenized competition, but signs of recovery are emerging as the sector shows a 20% quarter-on-quarter revenue growth in Q2 2025 [4][5]. Company Analysis - CanSino Biologics, a company with both innovative and commercial capabilities in the domestic vaccine sector, has been undervalued by the market, which still perceives it as a "single-product biotech" despite its comprehensive breakthroughs in commercialization, finance, pipeline, and globalization [1][10]. - CanSino's Q3 2025 financial report shows a revenue of approximately 693 million yuan, a year-on-year increase of 22.13%, and a net profit of approximately 14.44 million yuan, indicating a successful turnaround and enhanced profitability [11][12]. - The company has developed a unique four-valent meningococcal vaccine, which is the only one approved in China, and is expanding its market reach by increasing the age range for vaccination, thus raising its market ceiling [11]. - CanSino's cash flow from operating activities reached 33.49 million yuan, indicating strengthened self-sustaining capabilities that provide funding for pipeline advancement [12]. - The company has built five major technology platforms that create core barriers, supporting a diverse pipeline of innovative vaccines targeting various diseases, including a recently approved 13-valent pneumococcal polysaccharide conjugate vaccine [13][14]. - CanSino's internationalization strategy, which includes local production and technology output, is expected to unlock significant overseas market potential, particularly in regions like Southeast Asia and the Middle East [16][17].